Skip to main content

Nulojix FDA Approval History

FDA Approved: Yes (First approved June 15, 2011)
Brand name: Nulojix
Generic name: belatacept
Dosage form: Injection
Company: Bristol-Myers Squibb Company
Treatment for: Organ Transplant, Rejection Prophylaxis

Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.

Development timeline for Nulojix

DateArticle
Jun 16, 2011Approval FDA Approves Nulojix for Kidney Transplant Patients
May  3, 2010Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept
Mar  2, 2010FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
Sep  3, 2009Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application

See also

Nulojix (belatacept) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer